IgA-class autoantibodies against neuronal transglutaminase, TG6 in celiac disease: No evidence for gluten dependency

详细信息    查看全文

• 作者：Katri Lindfors^a ; ¹ ; Outi Koskinen^a ; ¹ ; Kaija Laurila^a ; Pekka Collin^b ; ^c ; P&#xe4 ; ivi Saavalainen^d ; Katri Haimila^e ; Jukka Partanen^e ; Markku M&#xe4 ; ki^a ; Katri Kaukinen^b ; ^c ; ^{katri.kaukinen@uta.fi"" rel=""nofollow}
• 关键词：Celiac disease ; Gluten ; Autoantibody ; Transglutaminase 6
• 刊名：Clinica Chimica Acta
• 出版年：2011
• 出版时间：11 June 2011
• 年：2011
• 卷：412
• 期：13-14
• 页码：1187-1190
• 全文大小：196 K

文摘

Background

It has been suggested that antibodies against transglutaminase (TG) 6 could serve as a biomarker to identify a subgroup of gluten-sensitive patients who may be at risk of developing neurological disease. We here investigated whether TG6-targeted autoantibodies are a characteristic feature of celiac patients, especially those with neurological symptoms, and further, whether such antibodies are gluten-dependent.

Methods

Serum IgA-class TG6 autoantibodies were measured in untreated and treated celiac patients with and without neurological manifestions and in non-celiac controls. The results were compared to TG2 autoantibody levels.

Results

During a gluten-containing diet the number of TG6 autoantibody-positive celiac patients with neurological problems (25 % ) did not significantly differ from that of TG6-seropositive patients without neurological impairment (16 % ) or from non-celiac controls (15 % ). This was in contrast to our finding in TG2 autoantibody-positive individuals, whose numbers differed significantly between all three study groups. On a gluten-free diet the levels of TG6 autoantibodies remained unchanged.

Conclusions

We conclude that the serum IgA-class TG6 autoantibody assay is not able to distinguish gluten-sensitive patients with neurological manifestations from celiac patients without neurological problems or from control subjects, and further, that TG6 autoantibodies are not gluten-dependent.